Rocket Pharmaceuticals, Inc. Common Stock (RCKT) Stock Price
RCKTStock
$2.18−45.50%52W
Market Cap$239.31M
P/E—
PEG Ratio—
Div yield—
Beta0.49
RCKT Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-50.02%
Price vs S&P 500 (4W)-32.01%
VGM Score31.84
RCKT Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $0.27 | -$0.38 | -244.19%(-$0.65) | |
| Q1 2026 | -$0.43 | -$0.42 | +3.08%(+$0.01) | |
| Q4 2025 | -$0.42 | -$0.38 | +10.45%(+$0.04) | |
| Q3 2025 | -$0.52 | -$0.45 | +12.68%(+$0.07) | |
| Q2 2025 | -$0.53 | -$0.59 | -11.38%(-$0.06) |
RCKT Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.65
3.65
3.65
3.65
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
RCKTRocket Pharmaceuticals, Inc. Common Stock | — | — | D | — | — | — | — | $2.18 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Rocket Pharmaceuticals, Inc. Common Stock
Rocket Pharmaceuticals is a late-stage biopharmaceutical company developing gene therapies for rare pediatric genetic diseases. Its pipeline includes five programs targeting Danon Disease, Fanconi Anemia, Leukocyte Adhesion Deficiency, Pyruvate Kinase Deficiency, and Infantile Malignant Osteopetrosis.